First Washington Corp’s Alaunos Therapeutics TCRT Stock Holding History

First Washington Corp’s Portfolio TCRT Stock Details TCRT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-65	Closed	-$42K	–	83
2019 Q3	$42K	Hold	65	–	–	0.02%	58
2019 Q2	$57K	Hold	65	–	–	0.03%	56
2019 Q1	$38K	Hold	65	–	–	0.02%	62
2018 Q4	$18K	Sell	65 -5	-7%	-$1.98K	0.01%	73
2018 Q3	$34K	Hold	70	–	–	0.02%	72
2018 Q2	$32K	Hold	70	–	–	0.02%	63
2018 Q1	$41K	Sell	70 -9	-11%	-$5.61K	0.02%	60
2017 Q4	$49K	Hold	79	–	–	0.02%	64
2017 Q3	$73K	Hold	79	–	–	0.04%	57
2017 Q2	$740	Hold	79	–	–	0.04%	58
2017 Q1	$75K	Sell	79 -1	-1%	-$931	0.04%	57
2016 Q4	$64K	Sell	80 -1	-1%	-$901	0.04%	57
2016 Q3	$69K	Hold	81	–	–	0.04%	56
2016 Q2	$67K	Hold	81	–	–	0.04%	63
2016 Q1	$91K	Hold	81	–	–	0.05%	61
2015 Q4	$101K	Sell	81 -1	-1%	-$1.65K	0.06%	61
2015 Q3	$110K	Hold	82	–	–	0.07%	66
2015 Q2	$147K	Buy	+82	New	+$127K	0.08%	62

Other funds holding TCRT

MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return

MVP

Miller Value Partners Sarasota, Florida $383M AUM 38.57% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

DCM

Discovery Capital Management South Norwalk, Connecticut $1.92B AUM 218.96% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

First Washington Corp's TCRT Position: Q4 2019 in Review

First Washington Corp sold out of Alaunos Therapeutics (TCRT) in Q4 2019, closing a stake of 65 shares — an estimated $42K sold.

First Washington Corp first reported a position in TCRT in Q2 2015 and held it in 18 quarters. The position peaked at $147K in Q2 2015. 148 funds tracked by Wall St. Rank hold TCRT as of Q4 2019.

First Washington Corp reported no remaining Alaunos Therapeutics position as of Q4 2019 after selling out during the quarter.
First Washington Corp sold 65 Alaunos Therapeutics shares in Q4 2019, an estimated $42K.
First Washington Corp first reported a position in Alaunos Therapeutics in Q2 2015 and held it in 18 quarters.
First Washington Corp's Alaunos Therapeutics position peaked at $147K in Q2 2015.
148 funds tracked by Wall St. Rank held Alaunos Therapeutics as of Q4 2019.

Based on First Washington Corp's 13F filing for Q4 2019, filed 10 Feb 2020.